

Han Soo Yoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1363451/publications.pdf>

Version: 2024-02-01

89
papers

1,348
citations

377584

21
h-index

563245

28
g-index

92
all docs

92
docs citations

92
times ranked

1791
citing authors

#	ARTICLE	IF	CITATIONS
1	Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 129-136.	1.5	3
2	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 2948-2960.	1.8	3
3	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. <i>Brain</i> , 2022, 145, 4448-4458.	3.7	9
4	Association of β -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.5	10
5	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. <i>Nutrition</i> , 2021, 83, 111090.	1.1	36
6	The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 1-6.	1.1	2
7	Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 239-249.	1.5	2
8	Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA) Trial. <i>Journal of Parkinson's Disease</i> , 2021, 11, 239-249.	2.3	6
9	Interaction of CSF β -synuclein and amyloid beta in cognition and cortical atrophy. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12177.	1.2	5
10	White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1411-1419.	2.2	22
11	Donepezil for mild cognitive impairment in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 4734.	1.6	10
12	Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1471-1487.	1.2	2
13	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2242-2248.	1.7	5
14	Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease. <i>Neurology</i> , 2021, 96, e2121-e2131.	1.5	32
15	Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. <i>Brain</i> , 2021, 144, 1127-1137.	3.7	30
16	Structural connectivity networks in Alzheimer's disease and Lewy body disease. <i>Brain and Behavior</i> , 2021, 11, e02112.	1.0	4
17	Different patterns of β -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. <i>Neurobiology of Aging</i> , 2021, 101, 199-206.	1.5	2
18	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 4203-4212.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-10.	1.5	9
20	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-11.	1.5	1
21	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <i>Scientific Reports</i> , 2021, 11, 14394.	1.6	7
22	Effects of statins on dopamine loss and prognosis in Parkinson's disease. <i>Brain</i> , 2021, 144, 3191-3200.	3.7	22
23	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. <i>Journal of Neuroscience Research</i> , 2021, 99, 2922-2931.	1.3	1
24	Neural correlates of self-awareness of cognitive deficits in non-demented patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 4022-4030.	1.7	3
25	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. <i>Neurobiology of Aging</i> , 2021, 106, 45-54.	1.5	9
26	Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. <i>Stem Cells International</i> , 2021, 2021, 1-10.	1.2	5
27	Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. <i>European Journal of Neurology</i> , 2020, 27, 318-326.	1.7	9
28	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. <i>Neurobiology of Aging</i> , 2020, 87, 11-17.	1.5	15
29	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	1.2	4
30	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e463-e468.	0.7	9
31	Factor analysis-derived cognitive profile predicting early dementia conversion in PD. <i>Neurology</i> , 2020, 95, e1650-e1659.	1.5	21
32	Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 140-143.	1.1	6
33	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2240-2249.	2.2	17
34	Effects of APOE4 on Alzheimer's disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. <i>Alzheimer's and Dementia</i> , 2020, 16, e037300.	0.4	0
35	Gender-specific effect of urate on white matter integrity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 41-47.	1.1	7
36	Clinical and striatal dopamine transporter predictors of β 2-amyloid in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e1344-e1352.	1.5	17

#	ARTICLE	IF	CITATIONS
37	Urate is closely linked to white matter integrity in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1029-1039.	1.7	4
38	Patterns of striatal dopamine depletion in early Parkinson disease. <i>Neurology</i> , 2020, 95, e280-e290.	1.5	25
39	White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 229-238.	1.7	16
40	Cognitive anosognosia is associated with frontal dysfunction and lower depression in Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 951-958.	1.7	10
41	Dopaminergic Depletion, β -Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> , 2020, 87, 739-750.	2.8	27
42	Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2020, 89, 63-70.	1.5	24
43	Sex-dependent association of urate on the patterns of striatal dopamine depletion in Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 773-778.	1.7	9
44	Impaired functional connectivity of sensorimotor network predicts recovery in drug-induced parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 16-21.	1.1	5
45	Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 5567.	1.6	7
46	Initial motor reserve and long-term prognosis in Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 92, 1-6.	1.5	15
47	Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2020, 13, 133-141.	0.7	22
48	Reply: ARSA gene variants and Parkinson's disease. <i>Brain</i> , 2020, 143, e48-e48.	3.7	0
49	Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1948-1956.	1.7	5
50	Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1541-1549.	1.5	4
51	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 105-109.	1.1	27
52	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	3.7	44
53	Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 10531.	1.6	35
54	Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2251-2260.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3784-3794.	1.9	41
56	Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1601-1610.	1.8	17
57	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1652-1660.	3.3	11
58	Mild cognitive impairment reverts have a favorable cognitive prognosis and cortical integrity in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 78, 168-177.	1.5	16
59	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.5	28
60	Dysautonomia is associated with structural and functional alterations in Parkinson disease. <i>Neurology</i> , 2019, 92, e1456-e1467.	1.5	21
61	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. <i>Neurology</i> , 2019, 92, e1468-e1478.	1.5	16
62	Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?. <i>Journal of Parkinson's Disease</i> , 2019, 9, 241-247.	1.5	9
63	Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 54-59.	1.1	20
64	Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 766-773.	1.7	25
65	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 299-301.	2.2	1
66	Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. <i>Journal of Movement Disorders</i> , 2019, 12, 113-119.	0.7	26
67	The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
73	A Nomogram for Predicting Amyloid PET Positivity in Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	1.2	38

74 A Novel Heterozygous *ANO3* Mutation with Basal Ganglia Dysfunction in a Patient with